Selective ITK and JAK3 Kinase Inhibitors for Autoimmune Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing selective inhibitors for ITK and JAK3 kinases is challenging due to the highly conserved ATP binding pocket within the TEC-kinase family and Janus family members, which complicates targeting these enzymes for treating autoimmune, inflammatory, and cancerous diseases without adverse effects.
Innovation Solution
Design and synthesis of covalent/irreversible and reversible 3,5-(un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine, and 5H-pyrrolo[2,3-b]pyrazine compounds that act as dual ITK and JAK3 inhibitors, utilizing proprietary FFDD technology to achieve selectivity, thereby modulating kinase activity for therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective JAK inhibitors are used, then broad kinase inhibition is achieved, but adverse effects such as hematopoiesis disruption and dyslipidemia occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features that target only particular kinase isoforms (JAK3 and ITK) while sparing others. The chemical structure incorporates specific substituents and core frameworks that confer selectivity for the target kinases' unique binding pockets, thereby achieving therapeutic effects without broad-spectrum inhibition that causes adverse effects like hematopoiesis disruption and dyslipidemia
2Object-affected harmful factors
If selective JAK3 inhibitors are developed, then adverse effects of JAK1 and JAK2 inhibition are avoided, but selectivity among highly conserved kinases becomes challenging
Solution Approach 1:
The patent applies segmentation by dividing the kinase target space into distinct segments - specifically targeting JAK3 and ITK while excluding JAK1, JAK2, and other TEC family members. The chemical compounds are designed with specific structural elements that fit only into the unique binding pockets of JAK3 and ITK, creating selective inhibition without cross-reactivity with other highly conserved kinases
Solution Approach 2:
The patent applies parameter changes by modifying chemical parameters such as substituent types, positions, and steric properties to fine-tune selectivity. By systematically varying these molecular parameters in the compound structure, the invention achieves optimal selectivity for JAK3 and ITK kinases despite their high conservation with other family members
3Reliability
If covalent/irreversible inhibitors are used, then potent and selective inhibition is achieved, but risk of off-target effects increases
Solution Approach 1:
The patent applies the intermediary principle by using reversible inhibitors as a mediating approach between covalent binding (high potency) and non-specific binding (off-target effects). The chemical compounds form reversible but high-affinity interactions with the target kinases through specific non-covalent bonds, achieving reliable inhibition while maintaining the ability to dissociate and reducing the risk of irreversible off-target effects
Data Source
AI summary
The present invention relates to compounds described by Formula I: salts thereof, their synthesis, and their use as ITK and JAK3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, Crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention.